Comparative Evaluation of Renoprotective Drug Regimens in Patients With Early-Stage Diabetic Kidney Disease
DOI:
https://doi.org/10.65327/kidneys.v15i1.602Keywords:
diabetic kidney disease, renoprotective therapy, drug mechanisms, conceptual framework, early interventionAbstract
A conceptual framework is presented to compare the mechanisms and theoretical effects of major renoprotective drug regimens used in the early stages of diabetic kidney disease. The condition develops through interconnected hemodynamic, metabolic, inflammatory, and fibrotic processes, and the therapeutic agents examined here influence different components of these pathways. The framework brings together established scientific knowledge on drug actions and the biological factors that drive early renal injury, offering a structured perspective on how each therapy may contribute to renal protection. Emphasis is placed on the importance of early therapeutic intervention, since kidney damage frequently begins before measurable declines in kidney function appear. The analysis also highlights the potential value of combining therapeutic agents to address multiple disease pathways at once. Overall, the framework supports improved treatment decision-making, encourages personalized therapeutic strategies, and identifies future research needs for empirical validation and comparative assessment of integrated drug regimens for early diabetic kidney disease.
Downloads
References
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clinical journal of the American Society of Nephrology. 2017 Dec 1;12(12):2032-45.
Thomas MC. Targeting the pathobiology of diabetic kidney disease. Advances in Chronic Kidney Disease. 2021 Jul 1;28(4):282-9.
Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. Journal of Histochemistry & Cytochemistry. 2012 Dec;60(12):976-86.
Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O, Icks A. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PloS one. 2016 Jan 26;11(1):e0147329.
Hsia HC, Eriksson E, Gurtner GC, Veves A, Hamdy O, Margolis DJ, Armstrong DG, Lavery LA, Grice EA, Schultz G, Conte MS. Management of Diabetic Wounds: Expert Panel Consensus Statement. Advances in Wound Care. 2025 Aug 20.
Navaneethan SD, Zoungas S, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, Tandon N. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Annals of internal medicine. 2023 Mar;176(3):381-7.
de Boer IH, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, Sadusky T. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney international. 2020 Oct 1;98(4):S1-15.
Hughes E, Wang XX, Sabol L, Barton K, Hegde S, Myakala K, Krawczyk E, Rosenberg A, Levi M. Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease. American Journal of Physiology-Renal Physiology. 2025 Oct 1;329(4):F510-47.
Lim AK. Diabetic nephropathy–complications and treatment. International journal of nephrology and renovascular disease. 2014 Oct 15:361-81.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, De Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes care. 2014 Oct 1;37(10):2864-83.
Jabareen Y. Building a conceptual framework: philosophy, definitions, and procedure. International journal of qualitative methods. 2009 Dec;8(4):49-62.
Imenda S. Is there a conceptual difference between theoretical and conceptual frameworks. Journal of social sciences. 2014 Feb 1;38(2):185-95.
Miles MB. Qualitative data analysis: An expanded sourcebook. Thousand Oaks. 1994.
Webster J, Watson RT. Analyzing the past to prepare for the future: Writing a literature review. MIS quarterly. 2002 Jun 1:xiii-xiii.
Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health information & libraries journal. 2009 Jun;26(2):91-108.
Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. Journal of the American Society of Nephrology. 2003 May 1;14(5):1358-73.
Fioretto P, Mauer M. Histopathology of diabetic nephropathy. InSeminars in nephrology 2007 Mar 1 (Vol. 27, No. 2, pp. 195-207). WB Saunders.
Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, Kaura A, Arkill KP, Harris K, Symonds C, Lacey K. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. Journal of the American Society of Nephrology. 2015 Aug 1;26(8):1889-904.
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013 Jan;93(1):137-88.
Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F, Tong X. Signaling pathways involved in diabetic renal fibrosis. Frontiers in cell and developmental biology. 2021 Jul 12;9:696542.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001 Sep 20;345(12):851-60.
Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England journal of medicine. 2001 Sep 20;345(12):861-9.
Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JF, McMurray JJ, Lindberg M, Rossing P, Sjöström CD. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020 Oct 8;383(15):1436-46.
Herrington Gómez WG, Staplin Gómez N, Wanner Gómez C, Green Gómez JB, Hauske Gómez SJ, Emberson Gómez JR. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-27.
Mann JF, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine. 2017 Aug 31;377(9):839-48.
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet Diabetes & endocrinology. 2018 Aug 1;6(8):605-17.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England journal of medicine. 2020 Dec 3;383(23):2219-29.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European heart journal. 2022 Feb 7;43(6):474-84.
Griffin L, B. Standridge J. A systematic review of randomized controlled trials examining the nephroprotective properties of antihypertensive medications. Current Hypertension Reviews. 2012 Aug 1;8(3):196-226.
Lasalvia P, Gil-Rojas Y, García Á. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research. 2022 Aug 18;22(6):955-64.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RH, Bhatt DL. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019 Jan 5;393(10166):31-9.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA cardiology. 2021 Feb 1;6(2):148-58.
Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JC, Kooy A, McCafferty K, Schernthaner G, Wanner C. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney international reports. 2022 Jan 1;7(1):36-45.
Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrology Dialysis Transplantation. 2025 Jan;40(Supplement_1):i3-17.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-66.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine. 2016 Jul 28;375(4):323-34.
Esposito P, Picciotto D, Cappadona F, Costigliolo F, Russo E, Macciò L, Viazzi F. Multifaceted relationship between diabetes and kidney diseases: beyond diabetes. World journal of diabetes. 2023 Oct 15;14(10):1450.
Rabbani SA, El-Tanani M, Kumar R, Saini M, El-Tanani Y, Sharma S, Aljabali AA, Hajeer E, Rizzo M. Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals. 2025 Jul 28;18(8):1130.
ISSN 2307-1257
ISSN 2307-1265
